REFERENCES
-
Prince AM, Horowitz B, Brotman B: Sterilisation of hepatitis and HTLV-III viruses by exposure to tri-n-butyl phosphate and sodium cholate. Lancet 1: 706-710, 1986
-
Horowitz B, Wiebe ME, Lippin A, et al: Inactivation of viruses in labile blood derivatives: I. Disruption of lipid enveloped viruses by tri-n-butyl phosphate detergent combinations. Transfusion 25: 516-522, 1985
-
Unpublished data in the files of Baxter Healthcare Corporation
-
Waldmann TA, Storber W: Metabolism of immunoglobulins. Prog Allergy 13: 1-110, 1969
-
Morell A, Riesen W: Structure, function and catabolism of immuno-globulins in Immunohemotherapy. Nydegger UE (ed), London, Academic Press, 1981, pp 17-26
-
Stiehm ER: Standard and special human immune serum globulins as therapeutic agents. Pediatrics 63: 301-319, 1979
-
Buckley RH: Immunoglobulin replacement therapy: Indications and contraindications for use and variable IgG levels achieved in Immunoglobulins: Characteristics and Use of Intravenous Preparations. Alving BM, Finlayson JS (eds), Washington, DC, U.S. Department of Health and Human Services, 1979, pp 3-8
-
Bunch C, Chapel HM, Rai K, et al: Intravenous Immune Globulin reduces bacterial infections in Chronic Lymphocytic Leukemia: A controlled randomized clinical trial. Blood 70 Suppl 1: 753, 1987
-
Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia: Intravenous immunoglobulin for the prevention of infection in Chronic Lymphocytic Leukemia: A randomized, controlled clinical trial. N Eng J Med 319: 902-907, 1988
-
Newburger J, Takahashi M, Burns JG, et al: The Treatment of Kawasaki Syndrome with Intravenous Gamma Globulin. New England Journal of Medicine 315: 341-347, 1986
-
Furusho K, Sato K, Soeda T, et al: High Dose Intravenous Gammaglobulin for Kawasaki Disease [letter]. Lancet 2: 1359, 1983
-
Nagashima M, Matsushima M, Matsucka H, Ogawa A, Okumura N: High Dose Gammaglobulin Therapy for Kawasaki Disease. Journal of Pediatrics 110: 710-712, 1987.
-
Data in the files of Baxter Healthcare Corporation
-
Furusho K, Hroyuki N, Shinomiya K, et al: High Dose Intravenous Gammaglobulin for Kawasaki Disease. Lancet 2: 1055-1058, 1984
-
Engle MA, Fatica NS, Bussel JB, O'Laughlin JE, Snyder MS, Lesser ML: Clinical Trial of Single-Dose Intravenous Gammaglobulin in Acute Kawasaki Disease. AJDC143: 1300-1304, 1989
-
Isawa M, Sugiyama K, Kawase A, et al: Prevention of Coronary Artery Involvement in Kawasaki Disease by Early Intravenous High Dose Gammaglobulin. In: Doyle EF, Engle MA, Gersony WM, Rashkind EJ, Talner NS, eds Pediatric Cardiology. New York: Springer-Verlag, 1986:1083-1085
-
Okuri M, Harada K, Yamaguchi H, et al: Intravenous Gammaglobulin Therapy in Kawasaki Disease: Trial of Low-Dose Gammaglobulin. In: Shulman ST, ed. Kawasaki Disease. New York: Alan R. Liss, 1987:433-439
-
Cayco AV, Perazella MA, Hayslett JP: Renal insufficiency after intravenous immune globulin therapy: A Report of Two Cases and an Analysis of the Literature. 1997; J Amer Soc Nephrology 8: 1788-1793
-
Burks AW, Sampson HA, Buckley RH: Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia: Detection of IgE antibodies to IgA. N Eng J Med 314: 560-564, 1986
-
Reinhart WH, Berchtold PE: Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 339 (8794): 662-664, 1992
-
Dalakas MC: High-dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events. Neurology 44 (2): 223-226, 1994
-
Harkness K, Howell SJL, Davies-Jones GAB: Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barre syndrome. Journal of Neurology Neurosurgery, Psychiatry 60 (5): 586-598, 1996
-
Woodruff RK, Grigg AP, Firkin FC, Smith IL: Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet ii (8500): 217-218, 1986
-
Silbert PL, Knezevic WV, Bridge DT: Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 42 (1): 257-258, 1992
-
Duhem C, Dicato MA, Ries F: Side effects of intravenous immune globulins. Clin Exp Immunol 97: (Suppl 1) 79-83, 1994
-
Winward DB, Brophy MT: Acute renal failure after administration of intravenous immunoglobulin: review of the literature and case report. 1995; Pharmacotherapy 15: 765-772
-
Phillips AO: Renal failure and intravenous immunoglobulin [letter, comment]. 1992; Clin Nephrol 36: 83-86
-
Anderson W, Bethea W: Renal lesions following administration of hypertonic solutions of sucrose. 1940; JAMA 114: 1983-1987
-
Lindberg H, Wald A: Renal changes following the administration of hypertonic solutions. 1939; Arch Intern Med 63: 907-918
-
Rigdon RH, Cardwell ES: Renal lesions following the intravenous injection of hypertonic solution of sucrose: A clinical and experimental study. 1942; Arch Intern Med 69: 670-690
-
Ochs HD, Lee ML, Fischer SH, et al: Efficacy of a New Intravenous Immunoglobulin Preparation in Primary Immunodeficient Patients. Clinical Therapeutics 9: 512-522, 1987
-
Tan E, Hajinazarian M, Bay, et al: Acute renal failure resulting from intravenous immunoglobulin therapy. 1993; Arch Neurology 50: 137-139
-
Brannagan TH 3rd, Nagle KJ, Lange DJ, Rowland LP: Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47 (3): 674-677, 1996
-
Haplea SS, Farrar JT, Gibson GA, Laskin M, Pizzi LT, Ashbury AK: Thromboembolic Events Associated with Intravenous Immunoglobulin Therapy: Neurology 48: A54, 1997
-
Kwan T, and Keith P: Stroke Following Intravenous Immunoglobulin Infusion in a 28-Year-Old Male with Common Variable Immune Deficiency: A Case Report and Literature Review. Canadian Journal of Allergy & Clinical Immunology 4: 250-253, 1999
-
Elkayam O, Paran D, Milo R, Davidovitz Y, Almoznino-Sarafian D, Zelster D, Yaron M, Caspi D: Acute Myocardial Infarction Associated with High Dose Intravenous Immunoglobulin Infusion for Autoimmune Disorders. A study of four cases. Ann Rheum Dis 59 (1): 77-80, 2000
-
Grillo JA, Gorson KC, Ropper AH, Lewis J, Weinstein R: Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology 57(9): 1699-1701, 2001
-
Gomperts ED, Darr F: Letter to the Editor: Reference article - Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology, 2002. In Press
BIBLIOGRAPHY
Bussel JB, Kimberly RP, Inman RD, et al: Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 62: 480-486, 1983
To enroll in the confidential, industry-wide Patient Notification System, call 1-888-UPDATE U (1-888-873-2838)
Baxter, Gammagard and Viaflex are trademarks of Baxter International, Inc., and are registered in the U.S. Patent and Trademark Office. Baxter Healthcare Corporation
Westlake Village, CA 91362 USA
U.S. License No. 140
Revised (August) 2002
30-5K-03-240
|